Login to Your Account



New entrant to clotting factor market; FDA clears Novo’s Tretten

By Catherine Shaffer
Staff Writer

Tuesday, December 24, 2013
Patients with congenital Factor XIII A-subunit deficiency will have access to a new recombinant treatment for the disorder beginning early in 2014, following the FDA’s approval of Novo Nordisk A/S’s Tretten (coagulation Factor XIII A-subunit [recombinant]) for routine prophylaxis of bleeding.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription